National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine–busulfan–antithymocyte globulin conditioning regimen

References

• Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945–956.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Vogelsang G, Flowers MED. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003;9:215–233.
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Weiden PL, Storb R, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone-marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989;73:1720–1728.
   PubMed Web of Science ®Google Scholar
• Weiden PL, Sullivan KM, Flournoy N, et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981;304: 1529–1533.
   PubMed Web of Science ®Google Scholar
• Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft versus host syndrome in man - a long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204–217.
   PubMed Web of Science ®Google Scholar
• Shulman HM, Kleiner D, Lee SJ, et al. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease: II. Pathology Working Group report. Biol Blood Marrow Transplant 2006;12:31–47.
   PubMed Web of Science ®Google Scholar
• Schultz KR, Miklos DB, Fowler D, et al. Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. Biol Blood Marrow Transplant 2006;12:126–137.
   PubMed Web of Science ®Google Scholar
• Arai S, Jagasia M, Storer B, et al. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood 2011;118:4242–4249.
   PubMed Web of Science ®Google Scholar
• Arora M, Nagaraj S, Witte J, et al. New classification of chronic GVHD: added clarity from the consensus diagnoses. Bone Marrow Transplant 2009;43:149–153.
   PubMed Web of Science ®Google Scholar
• Cho BS, Min CK, Eom KS, et al. Feasibility of NIH consensus criteria for chronic graft-versus-host disease. Leukemia 2009;23:78–84.
   PubMed Web of Science ®Google Scholar
• Jagasia M, Giglia J, Chinratanalab W, et al. Incidence and outcome of chronic graft-versus-host disease using national institutes of health consensus criteria. Biol Blood Marrow Transplant 2007;13:1207–1215.
   PubMed Web of Science ®Google Scholar
• Kim DY, Lee JH, Lee JH, et al. Reevaluation of the National Institutes of Health criteria for classification and scoring of chronic GVHD. Bone Marrow Transplant 2010;45:1174–1180.
   PubMed Web of Science ®Google Scholar
• Pidala J, Kim J, Anasetti C, et al. The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality. Haematologica 2011;96:1678–1684.
   PubMed Web of Science ®Google Scholar
• Terwey TH, Le Duc TM, Hemmati PG, et al. NIH-defined graft-versus-host disease and evidence for a potent graft-versus-leukemia effect in patients with acute lymphoblastic leukemia. Ann Oncol 2013;24:1363–1370.
   PubMed Web of Science ®Google Scholar
• Terwey TH, Vega-Ruiz A, Hemmati PG, et al. NIH-defined graft-versus-host disease after reduced intensity or myeloablative conditioning in patients with acute myeloid leukemia. Leukemia 2012;26:536–542.
   PubMed Web of Science ®Google Scholar
• Thepot S, Zhou J, Perrot A, et al. The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation. Leukemia 2010;24:1852–1858.
   PubMed Web of Science ®Google Scholar
• Vigorito AC, Campregher PV, Storer BE, et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood 2009;114:702–708.
   PubMed Web of Science ®Google Scholar
• Blaise D, Farnault L, Faucher C, et al. Reduced-intensity conditioning with fludarabin, oral busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies. Exp Hematol 2010;38: 1241–1250.
   PubMed Web of Science ®Google Scholar
• Devillier R, Crocchiolo R, Castagna L, et al. The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT. Bone Marrow Transplant 2012;47:639–645.
   PubMed Web of Science ®Google Scholar
• Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplant 1974;18:295–304.
   PubMed Web of Science ®Google Scholar
• Bullorsky EO, Shanley CM, Stemmelin GR, et al. Total lymphoid irradiation for treatment of drug-resistant chronic GVHD. Bone Marrow Transplant 1993;11:75–76.
   PubMed Web of Science ®Google Scholar
• Child FJ, Ratnavel R, Watkins P, et al. Extracorporeal photopheresis (ECP) in the treatment of chronic graft-versus-host disease (GVHD). Bone Marrow Transplant 1999;23:881–887.
   PubMed Web of Science ®Google Scholar
• de Lavallade H, Mohty M, Faucher C, et al. Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. Haematologica 2006;91:1438–1440.
   PubMed Web of Science ®Google Scholar
• Furlong T, Martin P, Flowers MED, et al. Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. Bone Marrow Transplantation 2009;44:739–748.
   PubMed Web of Science ®Google Scholar
• Inamoto Y, Flowers MED. Treatment of chronic graft-versus-host disease in2011. Curr Opin Hematol2011;18:414–420.
   Web of Science ®Google Scholar
• Mohty M, Marchetti N, El-Cheikh J, et al. Rituximab as salvage therapy for refractory chronic GVHD. Bone Marrow Transplant 2008;41:909–911.
   PubMed Web of Science ®Google Scholar
• Wolff D, Schleuning M, von Harsdorf S, et al. Consensus Conference on Clinical Practice in Chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2011;17:1–17.
   PubMed Web of Science ®Google Scholar
• Zaja F, Bacigalupo A, Patriarca F, et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant 2007;40:273–277.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
   Web of Science ®Google Scholar
• Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18:695–706.
   PubMed Web of Science ®Google Scholar
• Cox D. Regression models and life tables. J R Stat Soc 1972;34: 187–220.
   Google Scholar
• Sorror ML, Giralt S, Sandmaier BM, et al. Hematopoietic cell transplantation-specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 2007;110:4606–4613.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002;100:406–414.
   PubMed Web of Science ®Google Scholar
• Nordlander A, Mattsson J, Ringden O, et al. Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2004;10:195–203.
   PubMed Web of Science ®Google Scholar
• Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005;23:1993–2003.
   PubMed Web of Science ®Google Scholar
• Baron F, Labopin M, Niederwieser D, et al. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia 2012;26:2462–2468.
   PubMed Web of Science ®Google Scholar
• Valcarel D, Martino R, Caballero D, et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 2008;26:577–584.
   PubMed Web of Science ®Google Scholar
• Crocchiolo R, Esterni B, Castagna L, et al. Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases. Cancer 2013; 119:986–992.
   PubMed Web of Science ®Google Scholar
• Socie G. The NIH consensus criteria for chronic graft-versus-host disease: far more than just another classification. Leukemia 2009; 23:1–2.
   PubMed Web of Science ®Google Scholar
• Pavletic SZ, Martin P, Lee SJ, et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant 2006;12:252–266.
   PubMed Web of Science ®Google Scholar
• Couriel D, Carpenter PA, Cutler C, et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group report. Biol Blood Marrow Transplant 2006;12:375–396.
   PubMed Web of Science ®Google Scholar
• Martin PJ, Weisdorf D, Przepiorka D, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant 2006;12: 491–505.
   PubMed Web of Science ®Google Scholar
• Kuzmina Z, Eder S, Bohm A, et al. Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study. Leukemia 2012;26:746–756.
   PubMed Web of Science ®Google Scholar
• Inamoto Y, Martin PJ, Chai X, et al. Clinical benefit of response in chronic graft-versus-host disease. Biol Blood Marrow Transplant 2012;18:1517–1524.
   PubMed Web of Science ®Google Scholar
• Palmer JM, Lee SJ, Chai X, et al. Poor agreement between clinician response ratings and calculated response measures in patients with chronic graft-versus-host disease. Biol Blood Marrow Transplant 2012;18:1649–1655.
   PubMed Web of Science ®Google Scholar